Table 2. Allergy treatments and their impact on throat symptoms |
Table 2. Allergy treatments and their impact on throat
symptoms |
Table 2. Allergy treatments and their impact on
throat symptoms |
Table 2. Allergy treatments and their impact
on throat symptoms |
Table 2. Allergy treatments and their
impact on throat symptoms |
Study description |
Allergic population |
Allergy therapy |
Outcomes reported |
Recommendation |
Systematic review of RCTs
[72]
|
AR / AC
|
nsH1RAs
|
Only 3 RCTs were identified to include validated cough measures at
baseline and post treatment. All reported significant improvements in
subjective cough scores; atopic cough (relative improvement in cough
frequency score: 36.6 8.4%) seasonal allergic rhinitis-associated cough
(cough frequency score: 44.0 7.3% and cough intensity score: 65.7
8.3%); allergic rhinitis patients with comorbid asthma (4.0
1.3%)
|
Few clinical trials examining the benefits of nsH1RAs on chronic cough
outcomes have been conducted. There may be a subgroup of patients,
particularly those with seasonal AR related cough or atopic cough, whose
cough may improve with nsH1RA treatment. Further research is
required.
|
Prospective case series
[63]
|
AR
|
INCS and Loratadine
|
Improvement in both subjective and objective voice parameters during
pollen season.
|
The voice quality of patients with AR is improved with medical
treatment.
|
Korean cough guidelines
[73]
|
UACS (AR)
|
Various
|
|
For patients with suspected UACS
- Intranasal steroid can be considered in order to improve cough
(evidence, very low; recommendation, weak).
- Oral anti-histamine is recommended to improve cough (evidence,
very low; recommendation, strong).
- Nasal decongestant monotherapy is not recommended to improve
cough (evidence, expert opinion; recommendation, strong).
- Intranasal antihistamine is not considered to improve cough
(evidence, very low; recommendation, weak).
- Antibiotics are not recommended to improve cough (evidence,
expert opinion; recommendation, strong).
|
Prospective case series
50]
|
AR
|
Nasal saline nasopharyngeal irrigation (NSNPI) OR fluticasone propionate
nasal spray (FPNS)
|
Patients with suspected AR to house-dust mite reported less cough
symptoms after both interventions. VAS and nasal lavage inflammatory
markers showed significant improvement or change in both. Overall, a
better relief of the cough symptom after 30 days of treatment with NSNPI
compared with FPNS
|
NSPI reduces chronic cough in AR, more so than FNPS treatment
|
Prospective cohort study [74] |
UACS (AR) |
Montelukast 10mg daily |
Cough symptoms were significantly reduced in
patients with UACS or LPR, but not asthma. Treatment led to reductions
in lactoferrin and ECP levels, but not MPO. Pulmonary function was not
affected by treatment, |
Monteleukast treatment improves cough in
patients with UACS but not asthma |
ARIA clinical guidelines [75] |
UACS (AR) |
Various |
|
Patients with UACS should be prescribed a trial of nasal
corticosteroids and/or antihistamines for at least 4
weeks |